drugset / Trial / NCT07224932
Tolerability and Efficacy of CBD Extract for RLS Treatment
Phase 2
Not yet recruiting
60 enrolled
University of Colorado, Denver
Biopharmaceutical Research Company · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study plans to learn more about the safety and tolerability of high Cannabidiol (CBD) cannabis extract (BRC-002) for use in Idiopathic Restless Legs Syndrome. Symptoms and side effects experienced while taking the study drug will be tracked to determine if this medication is safe to use.
Timeline
- Start
- 2025-12-19
- Primary completion
- 2026-01-01
- Completion
- 2026-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BRC-002 | Unknown | 100 mg/ml | Oral |